Title
Category
Credits
Event date
Cost
Skin of Color Symposium: Dermatology Pearls for Treating Pediatric Patients of Color
  • LivDerm
  • TME
  • 1.75 AAPA Category I CME
  • 1.75 AMA PRA Category 1 Credit™
  • 1.75 ANCC
  • 1.75 Participation
$0.00
Pediatric patients with melanin-rich skin, or skin of color (SOC), can be disproportionately affected by numerous dermatologic conditions. Patients can be more susceptible or have a greater disease burden, especially with conditions such as acne, atopic dermatitis, psoriasis, pigmentary disorders, and hair disorders.
Clinical Brief: IL-13 inhibitors: Advances and Considerations for Managing Moderate-to-Severe Atopic Dermatitis
  • LivDerm
  • TME
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 ANCC
  • 0.25 Participation
$0.00
Timely and adequate treatment of atopic dermatitis (AD) is essential for helping to promote better long-term outcomes and quality of life and may help prevent the development of other atopic conditions.
Clinical Spotlight: Pediatric Diagnosis & Treatment for Rett Syndrome
  • TME
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC
  • 1.25 Participation
$0.00
Rett Syndrome is one of the most frequent causes of mental disability in females, with an estimated prevalence of 1 in 10,000 under the age of 12. It is characterized by normal early growth and development followed by a slowing of development, loss of purposeful use of the hands, distinctive hand movements, slowed brain and head growth, problems with walking, seizures, and intellectual disability.
Primer: Gamechangers in Alopecia Areata: Targeted Therapies for Patient-Centered Care
  • LivDerm
  • TME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Currently, the standard of care for patients with alopecia areata (AA) is insufficient, challenging clinicians to find effective treatments in practice. Recent findings have furthered understanding of AA, including the targeting of specific immunologic pathways, which has led to the development of Janus kinase (JAK) inhibitors as an emerging therapeutic option. Additionally, studies have uncovered risk factors for AA that clinicians need to be aware of when treating either pediatric or adult patients. 
Highlights of the 21st Annual South Beach Symposium 2023
  • LivDerm
  • TME
  • 2.00 AAPA Category I CME
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC
  • 2.00 Participation
$0.00
The ever-increasing impact of dermatologic conditions continues to be a major challenge for dermatologists and other health care providers in the United States (US). Dermatology practitioners diagnose and treat more than 3000 diseases across the age spectrum.  Therefore, clinicians are challenged to remain current in their knowledge and competence in the diagnosis and management of cutaneous disease.  
A New Age in Pediatric Psoriasis: Case-Based Learning for Inclusive Care
  • LivDerm
  • TME
  • 1.00 AAPA Category I CME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Psoriasis is an immune-mediated disease that currently affects more than 8 million Americans and 125 million people worldwide according to the World Psoriasis Day consortium. Symptoms of this disease are characterized by inflammation, commonly presenting as raised plaques and scales on the skin resulting from an overactive immune system.
Hidradenitis Suppurativa Clinician-Patient Summit
  • LivDerm
  • TME
  • 2.00 ACPE Pharmacy
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 ANCC
  • 2.00 Participation
$0.00
Hidradenitis suppurativa has significant impacts on patients’ quality of life, however, it remains underdiagnosed, misdiagnosed, or incorrectly treated.  Until recently, there was a scarcity of evidence about long-term management strategies and no evidence-based consensus guidelines.  The updated North American guidelines, as well as the growing armamentarium of agents in advanced clinical development, provide additional guidance for optimizing diagnosis and treatment of HS patients.  However, questions still remain about how to best individualize therapy and work as a partner with patients
AhR Agonists for Psoriasis: A Novel Mechanism for Treatment of PsO
  • LivDerm
  • TME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Psoriasis is a difficult disease to manage due to a variety of factors including fluctuations in disease severity, limited treatment options, and a limited understanding of the pathogenesis of disease. Recently, the first new topical for PsO since 1997 was approved for adults with plaque PsO. This agent is a novel, steroid-free aryl hydrocarbon receptor (AhR) agonist with no restrictions for duration, location, or extent of use.
Managing Psoriatic Arthritis Together: A Multidisciplinary Approach to Care Between Rheumatologists and Dermatologists
  • LivDerm
  • TME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Psoriatic arthritis (PsA) is a chronic, debilitating inflammatory disease that is associated with several comorbidities and often antecedes psoriasis. In fact, according to data from the National Psoriasis Foundation (NPF), approximately 30% of people with psoriasis develop PsA, with symptoms appearing around 10 years after the occurrence of cutaneous symptoms.
Clinical Brief: Updates in Managing Rare Diseases: Tips for the Practicing Dermatologist
  • LivDerm
  • TME
  • 0.25 AAPA Category I CME
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 ANCC
  • 0.25 Participation
$0.00
In the United States, a rare disease is defined as a condition that affects fewer than 200,000 people in the US. While each rare disease may not seem to affect so many people, there may be as many as 7,000 rare diseases affecting an estimated 25-30 million Americans. More specifically, there over 1,000 rare skin diseases that are often an extreme burden to the collective many of patients affected by these conditions.